- Home
- Publications
- Publication Search
- Publication Details
Title
Pegylated Liposomal Doxorubicin
Authors
Keywords
-
Journal
DRUGS
Volume 71, Issue 18, Pages 2531-2558
Publisher
Springer Nature
Online
2011-12-06
DOI
10.2165/11207510-000000000-00000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pegylated Liposomal Doxorubicin (Caelyx®) and Oral Vinorelbine in First-Line Metastatic Breast Cancer Patients Previously Treated with Anthracyclines
- (2014) L. Livi et al. JOURNAL OF CHEMOTHERAPY
- Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome
- (2012) Joan Bladé et al. Clinical Lymphoma Myeloma & Leukemia
- Plasma and cellular pharmacokinetics of doxorubicin after intravenous infusion of Caelyx™/Doxil® in patients with hematological tumors
- (2011) H. Richly et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- (2011) Alessandra Gennari et al. JOURNAL OF CLINICAL ONCOLOGY
- Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial
- (2011) Sandro Pignata et al. JOURNAL OF CLINICAL ONCOLOGY
- Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin
- (2010) Gabriele Buda et al. ANNALS OF HEMATOLOGY
- Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
- (2010) A. Poveda et al. ANNALS OF ONCOLOGY
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) N. Colombo et al. ANNALS OF ONCOLOGY
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) F. Cardoso et al. ANNALS OF ONCOLOGY
- Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198
- (2010) Antonio C. Wolff et al. BREAST CANCER RESEARCH AND TREATMENT
- Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study
- (2010) Emilio Alba et al. BREAST CANCER RESEARCH AND TREATMENT
- Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma
- (2010) Mary Cianfrocca et al. CANCER
- High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies
- (2010) Joshua P. Kesterson et al. CHEMOTHERAPY
- Estimates of cancer incidence and mortality in Europe in 2008
- (2010) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
- (2010) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluating New Regimens in Recurrent Ovarian Cancer: How Much Evidence Is Good Enough?
- (2010) Stephen A. Cannistra JOURNAL OF CLINICAL ONCOLOGY
- Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Delayed Neoplastic and Renal Complications in Women Receiving Long-term Chemotherapy for Recurrent Ovarian Cancer
- (2010) F. Muggia et al. JNCI-Journal of the National Cancer Institute
- Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
- (2009) J.-L. Harousseau et al. ANNALS OF ONCOLOGY
- Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE
- (2009) C. de la Fouchardiere et al. ANNALS OF ONCOLOGY
- Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer
- (2009) Mary E.R. OʼBrien ANTI-CANCER DRUGS
- Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer
- (2009) David Rossi et al. ANTI-CANCER DRUGS
- Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer
- (2009) Janos L. Tanyi et al. GYNECOLOGIC ONCOLOGY
- Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
- (2009) Joseph A. Sparano et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer
- (2009) Christos Christodoulou et al. ONCOLOGY
- Multicenter Phase II Study of Pegylated Liposomal Doxorubicin in Combination with Vinorelbine as First-Line Treatment in Elderly Patients with Metastatic Breast Cancer
- (2009) Brigitte Mlineritsch et al. Oncology Research and Treatment
- Prognostic factors for multiple myeloma in the era of novel agents
- (2008) J. Blade et al. ANNALS OF ONCOLOGY
- Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy
- (2008) Pieter Sonneveld et al. CANCER
- Pegylated Liposomal Doxorubicin
- (2008) Greg L Plosker DRUGS
- Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of experts
- (2008) Roger von Moos et al. EUROPEAN JOURNAL OF CANCER
- British HIV Association guidelines for HIV-associated malignancies 2008
- (2008) M Bower et al. HIV MEDICINE
- Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer
- (2008) Gabriella Ferrandina et al. JOURNAL OF CLINICAL ONCOLOGY
- Concept and Clinical Evaluation of Carrier-Mediated Anticancer Agents
- (2008) W. C. Zamboni ONCOLOGIST
- Cardiac safety profile of pegylated liposomal doxorubicin reaching or exceeding lifetime cumulative doses of 550 mg/m2in patients with recurrent ovarian and peritoneal cancer
- (2007) Y. YILDIRIM et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started